Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab and Oxaliplatin in Metastatic Breast Cancer
NCT00297596Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Feb 2006
- Primary completion
- Oct 2008
- Modality
- Antibody Conjugates, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of trastuzumab and oxaliplatin in breast cancer, sponsored by SCRI Development Innovations. Primary endpoint: Objective Response Rate at 18 months. Started Feb 2006; status: completed.
02
Drugs
trastuzumaboxaliplatin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00297596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00297596.